Abstract
Introduction There is a lack of treatment options for individuals with drug resistant idiopathic generalized epilepsy (IGE). Small, limited case series suggest that centromedian thalamus deep brain stimulation (CM-DBS) may be an effective treatment option. The optimal CM-DBS target for IGE is underexamined. Here, we present a retrospective analysis of CM-DBS targeting and efficacy for five patients with drug-resistant IGE.
Methods This single-center case series study included all patients with drug resistant IGE treated with CM-DBS to date. Seizure outcomes were measured with patient-reported seizure frequency. Baseline frequency was taken from the visit immediately before implantation, and it was compared with the seizure frequency from the most recent visit. Stimulation parameters from last clinic visit were used to determine the volume of tissue activated (VTA) by DBS. Lead proximity to target, and VTA overlap with CM nucleus was performed using an open-source toolbox (Lead-DBS 3.0, SimBio/FieldTrip). Associations between the intersection of the VTA and CM nucleus, and seizure outcomes were measured using Spearman’s rank correlation.
Results Five patients were identified and included in the study. Median age was 31 (22-45). Median baseline frequency of convulsive seizure was 1.5 per month (0-3.5). Median follow-up time was 13 months (3-23). Median convulsive seizure frequency reduction was 60% (−200-100%). One patient had only absence seizures, with >99% absence seizure frequency reduction. Four out of five subjects had electrode contacts positioned within the CM nucleus target, all of whom had >50% reduction in primary semiology seizure frequency (3 subjects with convulsive seizures, 1 patient with absence seizures). Spearman’s rho was 0.90 (P=0.025). Volumetric “sweet-spot” mapping revealed best outcomes were correlated with stimulation of the middle ventral CM nucleus.
Conclusion Our findings suggest that CM-DBS can be an effective treatment for patients with IGE. The extent of overlap between the VTA by DBS and CM nucleus is correlated with the degree of seizure reduction, highlighting the importance of accurate targeting and volumetric targeting analysis.
Competing Interest Statement
G.A.W., B.N.L., J.J.V.V., declare intellectual property licensed to Cadence Neuroscience (BNL waived contractual rights). S.A. is a consultant for Blackrock Neurotech. B.N.L. declares intellectual property licensed to Seer Medical (contractual rights waived). G.A.W. licensed intellectual property and serves on the scientific advisor board of NeuroOne, Inc. B.N.L., G.A.W, N.M.G. are investigators for the Medtronic Deep Brain Stimulation Therapy for Epilepsy PostApproval Study. B.N.L is an investigator for the Neuroelectrics tDCS for Patients with Epilepsy Study. J.J.V.V., G.A.W., B.N.L., N.M.G. are investigators for the NeuroPace RNS NAUTILUS study. N.M.G has consulted for NeuroOne, Inc. (funds to Mayo Clinic). B.N.L has consulted for Epiminder, Medtronic, Neuropace, and Philips Neuro (all funds to Mayo Clinic). The remaining authors declare no competing interests.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Mayo Clinic gave ethical approval for this work (ID: 23-009255)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be made available upon reasonable request.
